‘Bridging” is a term that refers to the use of short-acting anticoagulants (heparin or LMWH) for a period of time during interruption of warfarin therapy when the INR is not within a therapeutic range.
There is no established single bridging regimen. Variability exists in the type of anticoagulant, intensity of anticoagulation and timing of perioperative administration. In considering which regimen and administration approach to use, there are several points to consider:
See “Peri-Procedural Anticoagulation Recommendations” for more information.
Perioperative Management of Antithrombotic Therapy: Antithrombotic Therapy and Prevention of Throbosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141;e326S-e350S
UC San Diego | School of Medicine | Health Sciences